Search: (WFRF:(D'Amato Mauro)) >
Microscopic colitis
-
Burke, Kristin E.Gastroenterology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
(author)
Microscopic colitis
- Article/chapterEnglish2021
Publisher, publication year, extent ...
-
2021-06-10
-
Nature Publishing Group,2021
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:oru-92321
-
https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-92321URI
-
https://doi.org/10.1038/s41572-021-00273-2DOI
-
http://kipublications.ki.se/Default.aspx?queryparsed=id:146939849URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:for swepub-publicationtype
Notes
-
Funding Agencies:American College of Gastroenterology Clinical Research Award United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA AG068390
-
Microscopic colitis (MC) is an inflammatory disease of the large intestine associated with urgent watery diarrhoea. MC may occur in people of all ages, although the disease primarily affects older women. Once believed to be rare, MC is now known to be a common cause of chronic watery diarrhoea in high-income countries, affecting 1 in 115 women and 1 in 286 men during their lifetime in Swedish population-based estimates. An inappropriate immune response to disturbances in the gut microenvironment is implicated in the pathogenesis of MC. Evidence also supports an underlying genetic basis for disease. The diagnosis of MC relies on clinical symptoms and microscopic assessment of colonic biopsy samples. MC is categorized histologically into collagenous colitis, lymphocytic colitis and their incomplete forms. The mainstay of treatment includes the use of budesonide, with or without adjunctive therapies, and withdrawal of offending drugs. Emerging studies suggest a role for biologicals and immunosuppressive therapies for the management of budesonide-refractory or budesonide-dependent disease. MC can have a substantial negative effect on patient quality of life. The outlook for MC includes a better understanding of the immune response, genetics and the microbiome in disease pathogenesis along with progress in disease management through robust clinical trials.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
D'Amato, MauroKarolinska Institutet
(author)
-
Ng, Siew C.Department of Medicine and Therapeutics, State Key Laboratory of Digestive Disease, LK Institute of Health Science, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China
(author)
-
Pardi, Darrell S.Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA
(author)
-
Ludvigsson, Jonas F.,1969-Karolinska Institutet,Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; Department of Paediatrics, Örebro University Hospital, Örebro, Sweden(Swepub:oru)jsln
(author)
-
Khalili, HamedGastroenterology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA; Institute of Environmental Medicine, Nutrition Epidemiology, Karolinska Institutet, Solna, Sweden
(author)
-
Karolinska InstitutetGastroenterology Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Clinical and Translational Epidemiology Unit, Massachusetts General Hospital, Boston, MA, USA
(creator_code:org_t)
Related titles
-
In:Nature reviews. Disease primers: Nature Publishing Group7:12056-676X
Internet link
Find in a library
To the university's database